What You Should Know:
- SandboxAQ, a leader in artificial intelligence (AI) solutions, today announced a strategic partnership with Google Cloud to integrate and optimize its platform of Large Quantitative Models (LQMs) on Google Cloud.
- The collaboration will leverage Google Cloud's robust infrastructure and advanced capabilities to enhance the performance and scalability of SandboxAQ's AI solutions while making them more accessible to customers through Google Cloud
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Guardant Health and ConcertAI Partner to Unlock Cancer Insights with Multi-Modal Real-World Data
What You Should Know:
- Guardant Health, a provider in precision oncology, and ConcertAI, a real-world evidence (RWE) and AI technology company in oncology, announced a strategic collaboration that will provide biopharmaceutical companies with access to a first-of-its-kind multi-modal real-world data (RWD) solution.
- The partnership integrates comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling information, offering a deeper
Read More
TetraScience & Microsoft Partner to Advance Scientific AI in Biopharma
What You Should Know:
- TetraScience, a provider of scientific data cloud solutions announced a strategic collaboration with Microsoft to accelerate the adoption of artificial intelligence (AI) in the biopharmaceutical industry.
- The strategic partnership combines TetraScience's Scientific Data and AI Cloud with the power and security of Microsoft Azure, creating a robust platform for scientific organizations to extract valuable insights from their complex experimental
Read More
Is AI Failing Drug Development? The Unseen Challenges
For over a decade, we've heard about AI's transformative potential in therapeutics (Tx), but where's the evidence? Has it all been hype? Can AI still revolutionize Tx? Or is there something the AI experts aren't telling us?
First, some facts. The process of Tx development—from early clinical trials to FDA approval—is excruciatingly slow (over 10 years), expensive (over $2B, especially for immunotherapy drugs), and comes with a low probability of success (5% in Immune-Oncology, and similarly
Read More
Increasing Participation in Muscular Dystrophy Clinical Trials
Muscular Dystrophy (MD) refers to a group of rare genetic conditions that cause progressive muscle weakness and degeneration in patients. Some forms of MD, such as Duchenne Muscular Dystrophy (DMD), can be life threatening to heart and respiratory functions.
But recent research found that among 3,661 U.S. patients with Muscular Dystrophy, only 33% of those with Duchenne and 12% of those with Becker Muscular Dystrophy - a similar but milder and later-onset MD condition - have previously
Read More
Lantheus (LNTH) Acquires Life Molecular Imaging for $750M
What You Should Know:
- Lantheus Holdings, Inc. (NASDAQ: LNTH), a leading radiopharmaceutical company, announced a definitive agreement to acquire Life Molecular Imaging Ltd. for $350M upfront and up to an additional $400M in potential earn-out and milestone payments.
- The strategic acquisition strengthens Lantheus' position in the radiopharmaceutical market and establishes a commercial presence in the Alzheimer's disease (AD) space.
Life Molecular Imaging
Read More
Broad Institute & Manifold Partner to Develop AI Research Platform
What You Should Know:
- The Broad Institute of MIT and Harvard is collaborating with Manifold, a leader in AI-powered research infrastructure, to develop a next-generation platform for biomedical research.
- The strategic partnership aims to enhance data analysis, secure sharing, and global collaboration, empowering scientists worldwide to accelerate discovery.
Manifold: Accelerating Biomedical Research with AI
Founded in 2016, Manifold's AI-powered platform streamlines
Read More
Rubicon Founders Invests $165M in Caidya to Fuel Global Expansion
What You Should Know:
- Caidya, a global mid-sized clinical research organization (CRO), announced today a $165 million strategic growth investment from funds managed by Rubicon Founders, a healthcare investment firm focused on building and growing transformative companies.
- The strategic investment will support Caidya's continued expansion and its mission to accelerate the development of innovative therapies for unmet medical needs.
Fueling Growth and Strategic
Read More
Open Source in Life Sciences: Balancing Innovation and Compliance
Data science teams in the life sciences industry are experiencing a significant change that will transform how clinical data is analyzed, opening the door to new possibilities for innovation. The transition isn’t happening overnight, but such incremental approaches are necessary to ensure success in such a highly regulated environment.
For decades, SAS was “it” in life sciences. If you wanted to be a data scientist in the industry, you had to know SAS. However, recently there has been a move
Read More
Medidata Platform Enhances Clinical Trial Efficiency for Bristol Myers Squibb
What You Should Know:
- Medidata, a Dassault Systèmes brand and a leader in clinical trial solutions for the life sciences industry, has announced an extended and expanded partnership with Bristol Myers Squibb (BMS).
- This collaboration aims to enhance clinical research processes, improve patient outcomes, and foster advancements in personalized healthcare.
Medidata and Bristol Myers Squibb Strengthen Partnership to Advance Clinical Research and Personalized Healthcare
As
Read More
